论文部分内容阅读
目的:观察艾迪注射液联合TP方案治疗中晚期非小细胞肺癌(NSCLC)的临床疗效。方法:将58例患者随机分为2组,治疗组30例采用艾迪注射液配合TP方案治疗,对照组28例采用TP方案治疗,2组均以21天为1周期,完成2周期后评价疗效。结果:治疗组和对照组的有效率分别为46.7%和42.9%,2组比较,差异无显著性意义(P>0.05);治疗组主要毒副反应情况和生活质量情况分别与对照组比较,差异均有显著性意义(P<0.05)。结论:艾迪注射液联合TP方案治疗NSCLC有较好的近期临床疗效,对减轻化疗毒副反应和提高生活质量方面均有较好的作用。
Objective: To observe the clinical efficacy of Aidi Injection and TP regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Fifty-eight patients were randomly divided into two groups. The treatment group (30 cases) was treated with Aidi Injection and TP regimen. The control group (28 cases) was treated with TP regimen. The two groups were treated with 21 days and one cycle Efficacy. Results: The effective rates of the treatment group and the control group were 46.7% and 42.9%, respectively. There was no significant difference between the two groups (P> 0.05). The main side effects and quality of life in the treatment group were compared with those in the control group, respectively. The difference was significant (P <0.05). Conclusion: Aidi injection combined with TP regimen in the treatment of NSCLC has good clinical efficacy in the near future, and has a good effect on alleviating chemotherapy side effects and improving quality of life.